- Allakos (ALLK +7.9%) has announced the publication of results from Phase 2 study of lirentelimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis in the New England Journal of Medicine.
- All AK002 dose arms showed clinically meaningful and statistically significant benefits compared to placebo on all prespecified primary and secondary endpoints, including gastrointestinal tissue eosinophil counts and patient-reported disease symptoms.
- Last year, the company announced positive top line data from the study, demonstrating a 95% reduction in the number of eosinophils (a type of white blood cell associated with inflammation/infection) in gastrointestinal tissue compared to a 10% increase in the control group (p<0.0001). All secondary endpoints were also met.